Abstract: Buparlisib (BKM120) is an orally bioavailable, pan-class I phosphoinositide 3-kinase (PI3K) inhibitor that has garnered significant interest as a targeted cancer therapeutic. In the context of glioblastoma multiforme (GBM), a highly aggressive brain tumor frequently characterized by PI3K-AKT-mTOR pathway activation via PTEN loss, buparlisib represents a promising candidate due to its ability to cross the blood-brain barrier. Preclinical models have demonstrated its robust antitumor and antiangiogenic activities, as well as synergistic effects when combined with standard chemotherapies like temozolomide. However, despite its potent ATP-competitive inhibition of PI3K and suppression of downstream signaling, single-agent buparlisib has shown only marginal clinical efficacy in recurrent GBM. Furthermore, its central nervous system penetration has been associated with psychiatric adverse events. Current research directions are therefore focused on combination therapies and biomarker-driven clinical trials to maximize its therapeutic potential and overcome resistance in GBM patients.
1. Introduction
The phosphoinositide 3-kinase (PI3K)/AKT/mammalian target of rapamycin (mTOR) signaling pathway is a critical regulatory network that is frequently hyperactivated in various human cancers, driving tumor cell growth, survival, and proliferation [11]. In glioblastoma multiforme (GBM), this pathway is commonly activated due to the loss or mutation of the tumor suppressor PTEN [2]. Buparlisib (BKM120) is a potent, highly specific, and orally available small molecule inhibitor of the pan-class I PI3K family [7][11]. Because of its favorable pharmacokinetic profile and its distinct ability to penetrate the blood-brain barrier, buparlisib has emerged as a highly promising targeted therapeutic agent for the treatment of central nervous system malignancies, particularly GBM [2].
2. Pharmacological Activity
Preclinical investigations have highlighted the robust pharmacological activity of buparlisib in GBM. In both GBM cell lines and mouse xenograft models, buparlisib demonstrated significant antitumor activity that occurred independently of the tumor's PTEN or EGFR mutational status [2]. Furthermore, buparlisib exhibited synergistic antitumor effects when administered in combination with the alkylating agent temozolomide in PTEN-null GBM mouse xenografts [2]. Beyond its direct cytotoxic effects on tumor cells, buparlisib also displays antiangiogenic properties; in vivo studies have shown that it effectively blocks VEGF-induced neovascularization [16]. Interestingly, at high concentrations, buparlisib has been observed to cause cell death across various cellular systems irrespective of their level of PI3K addiction, suggesting that it may possess additional pharmacological activities beyond PI3K pathway suppression [5].
3. Molecular Mechanism of Action
Buparlisib functions as an ATP-competitive inhibitor that specifically targets all four catalytic p110 subunits (α, β, δ, and γ) of class I PI3K [7]. It exhibits a high degree of specificity, demonstrating more than 10-fold selectivity for PI3K over mTOR [16]. By competitively binding to the ATP-binding site of the PI3K kinase domain, buparlisib inhibits the phosphorylation of phosphatidylinositol 4,5-bisphosphate (PIP2) and prevents the production of the secondary messenger phosphatidylinositol (3,4,5)-trisphosphate (PIP3) [7][11]. The depletion of PIP3 subsequently blocks the recruitment and activation of downstream effectors, effectively shutting down the PI3K/AKT signaling cascade and disrupting tumor cell survival and proliferation [7]. Additionally, biochemical and cell-based assays suggest that buparlisib may possess a unique mechanism of action independent of PI3K inhibition; at high doses, it has been shown to interfere with microtubule assembly, thereby inducing cell cycle arrest at the G2-M phase [5][16].
4. Structure-Activity Relationship (SAR)
While exhaustive structural derivatives are not detailed in the provided literature, the structure-activity relationship of buparlisib is defined by its design as a small molecule inhibitor (SMI) optimized for oral bioavailability and kinase selectivity [7]. Its molecular architecture allows it to fit precisely into the ATP-binding pocket of the PI3K catalytic heterodimers, ensuring potent pan-class I inhibition while maintaining a significant selectivity window over structurally related kinases like mTOR [7][16]. Crucially, the physicochemical properties of buparlisib facilitate its crossing of the blood-brain barrier, a structural advantage that is essential for its application in neuro-oncology and the treatment of glioblastoma [2].
5. Current Limitations
Despite strong preclinical rationale, the clinical translation of buparlisib in GBM has faced significant hurdles. In a Phase II clinical trial involving patients with recurrent GBM, single-agent buparlisib demonstrated only marginal clinical activity, yielding a median progression-free survival (PFS) of just 1.8 months [2]. Although the trial utilized a target enrichment strategy—enrolling patients based on PI3K pathway activation defined by PIK3CA mutations, PTEN mutations, or PTEN deletions—no correlation was observed between treatment efficacy and pathway activation status [2]. Furthermore, the very property that makes buparlisib attractive for GBM—its central nervous system (CNS) penetration—has proven disadvantageous regarding its toxicity profile. Patients treated with buparlisib have frequently experienced psychiatric adverse events, including depression, anxiety, and in rare cases, suicidal ideation [15][48]. Other common dose-limiting toxicities include fatigue, nausea, anorexia, hyperglycemia, and elevated hepatic transaminases [15].
6. Future Perspectives
To address the limitations of buparlisib monotherapy, current research in GBM is pivoting toward combination regimens and refined biomarker strategies. Mandatory tissue collection and next-generation sequencing are being integrated into trial designs to better understand resistance mechanisms and identify true predictive biomarkers of response [6]. Ongoing Phase IB/II studies are evaluating buparlisib in combination with chemotherapeutic agents such as carboplatin or lomustine, as well as with the anti-VEGF antibody bevacizumab, in patients with recurrent GBM that has relapsed after standard therapy [6]. Additionally, a Phase I trial is investigating the integration of buparlisib with standard-of-care radiation therapy and temozolomide in newly diagnosed GBM patients [6]. These combinatorial approaches, guided by rigorous molecular profiling of archival and fresh tumor biopsies, hold the potential to overcome intrinsic resistance and improve the therapeutic index of PI3K inhibitors in glioblastoma [6].
